Healthcare Industry News: Vinorelbine
News Release - June 9, 2006
Novacea Appoints Paul Laland as Vice President, Corporate CommunicationsSOUTH SAN FRANCISCO, CA--(Healthcare Sales & Marketing Network)--Jun 9, 2006 -- Novacea, Inc. (NasdaqNM:NOVC ) announced today that Paul Laland has been appointed Vice President of Corporate Communications. Mr. Laland, with more than 20 years of experience in domestic and international pharmaceutical and biotechnology communications, joins Novacea from VaxGen, Inc., a biopharmaceutical company, where he served as Vice President of Public Affairs.
"With an eye toward commercialization of novel oncology drugs, Paul's extensive experience in product development, late-stage clinical trials, and product launches is an important asset for Novacea," said Brad Goodwin, chief executive officer of Novacea. "Having been a key member of the teams that launched important oncology products such as RituxanŽ and HerceptinŽ, Paul will be instrumental in leading us through communications opportunities with our media, investor, government and advocacy constituents."
At VaxGen, Mr. Laland played a leading role in formulating and managing the company's overall communications strategy with key national and local media, advocacy and professional groups, policymakers on Capitol Hill and investors. Prior to VaxGen, Mr. Laland served as Senior Partner and Co-chair of the Global Healthcare Practice at Fleishman-Hillard International Communications, Inc., where he established and led the Life Sciences Group on the West Coast. He has also served in various corporate communications positions at Genentech, Inc., Synergen, Inc., G.D. Searle and Deltagen, Inc. prior to joining Fleishman-Hillard. Mr. Laland holds a bachelor's degree in communications and marketing from the University of Utah.
Novacea, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing novel cancer therapies. Novacea has three product candidates in clinical trials, including DN-101, which currently is in a Phase 3 clinical trial for androgen-independent prostate cancer, or AIPC. Novacea's second drug candidate, oral Vinorelbine, is expected to enter a registration trial for metastatic breast cancer in the second half of 2006. A third product candidate, AQ4N, is expected to advance into a Phase 1/2 clinical trial in the second half of 2006 for the treatment of glioblastoma multiforme in combination with radiation and chemotherapy.
Note: Except for the historical information contained herein, the matters set forth in this press release, including statements as to development, clinical studies, regulatory review and approval, and commercialization of products, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: early stage of development; the focus, conduct, enrollment and timing of our clinical trials; regulatory review and approval of product candidates; commercialization of products; market acceptance of products; funding requirements; intellectual property protection for our product candidates; competing products and other risks detailed from time to time under the heading "Risk Factors" in our most recent Registration Statement on Form S-1, as amended, and as may be updated from time to time by our future filings under the Securities Exchange Act. If one or more of these risks or uncertainties materialize, or if any underlying assumptions prove incorrect, our actual performance or results may vary materially from any future performance or results expressed or implied by these forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.